Soleno Therapeutics reported that sales of its rare disease drug Vykat XR exceeded investor forecasts in its first full quarter on the market. Vykat XR, approved in late March 2025 for Prader-Willi syndrome, treats a rare genetic disorder that causes an insatiable appetite. Following its commercial launch, Soleno announced sales revenues surpassing $31-33 million for the second quarter. The company is raising $200 million in a follow-on stock sale, buoyed by the drug’s robust market reception. The positive market response reflects growing industry attention on therapies addressing rare genetic disorders.